Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature

详细信息    查看全文

• 作者：Abraham C. J. Stork (1)
  W-Ludo van der Pol (1)
  Hessel Franssen (1)
  Bart C. Jacobs (2)
  Nicolette C. Notermans (1)
  
• 关键词：Monoclonal gammopathy ; Myelin ; associated glycoprotein ; Ganglioside ; Polyneuropathy ; Nerve conduction studies
• 刊名：Journal of Neurology
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：261
• 期：7
• 页码：1398-1404
• 全文大小：172 KB
• 参考文献：1. Kuijf ML, Eurelings M, Tio-Gillen AP, van Doorn PA, van den Berg LH, Hooijkaas H, Stork ACJ, Notermans NC, Jacobs BC (2009) Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73:688-95 CrossRef
  2. Steck AJ, Stalder AK, Renaud S (2006) Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol 19:458-63 CrossRef
  3. Eurelings M, Ang CW, Notermans NC, van Doorn PA, Jacobs BC, van den Berg LH (2001) Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology 57:1909-912 CrossRef
  4. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65:286-93 CrossRef
  5. Attarian S, Boucraut J, Hubert AM, Uzenot D, Delmont E, Verschueren A, Franques J, Azulay JP, Pouget J (2006) Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry 81:61-4 CrossRef
  6. Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B, For the RIMAG Study Group (France and Switzerland) (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80:2217-225 CrossRef
  7. Susuki K, Yuki N, Hirata K (2001) Features of sensory ataxic neuropathy associated with anti-GD1b IgM antibody. J Neuroimmunol 112:181-87 CrossRef
  8. Willison HJ, O’Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, Fuhr P, Ford H, Hahn A, Renaud S, Katifi HA, Ponsford S, Reuber M, Steck A, Sutton I, Schady W, Thomas PK, Thompson AJ, Vallat JM, Winer J (2001) The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124:1968-977 CrossRef
  9. Willison HJ, Yuki N (2001) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591-625 CrossRef
  10. Niermeijer JM, Fischer K, Eurelings M, Franssen H, Wokke JH, Notermans NC (2010) Prognosis of polyneuropathy due to IgM monoclonal gammopathy. Neurology 74:204-12 CrossRef
  11. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timann D, Honnorat J, Nighoghossian N, Manyam B (1997) International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145:205-11 CrossRef
  12. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA, Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2003) Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 74:99-04 CrossRef
  13. Erdmann PG, Teunissen LL, van Garderen FR, van Genderen FR, Notermans NC, Lindeman E, Helders PJ, van Meeteren NL (2005) Functioning of patients with chronic idiopathic axonal polyneuropathy (CIAP). J Neurol 254:1204-211 CrossRef
  14. Franssen HF, Notermans NC (2006) Length dependence in polyneuropathy associated with IgM gammopathy. Ann Neurol 59:365-71 CrossRef
  15. Ilyas AA, Willison HJ, Dalakas MC, Whitaker JN, Quarles RH (1988) Identification and characterization of gangliosides reacting with IgM paraproteins in three patients with neuropathy associated with biclonal gammopathy. J Neurochem 51:851-58 CrossRef
  16. Bollensen E, Schipper HI, Steck AJ (1989) Motor neuropathy with activity of monoclonal IgM antibody to GD1a ganglioside. J Neurol 236:353-55 CrossRef
  17. Daune GC, Farrer RG, Dalakas MC, Quarles RH (1992) Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. Ann Neurol 31:683-85 CrossRef
  18. Younes-Chennoufi AB, Léger JM, Hauw JJ, Preud’homme JL, Bouche P, Aucouturier P, Ratinahirana H, Lubetzki C, Lyon-Caen O, Baumann N (1992) Ganglioside GD1b is the target antigen for a biclonal IgM in a case of sensory-motor axonal polyneuropathy: involvement of / N-acetylneuraminic acid in the epitope. Ann Neurol 32:18-3 CrossRef
  19. Carpo M, Nobile-Orazio E, Meucci N, Gamba M, Barbieri S, Allaria S, Scarlato G (1996) Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann Neurol 39:539-43 CrossRef
  20. Carpo M, Pedotti R, Lolli F, Pitrola A, Allaria S, Scarlato G, Nobile-Orazio E (1998) Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci 155:186-91 CrossRef
  21. Oga T, Kusunoki S, Fujimura H, Kuboki T, Yoshida T, Takai T (1998) Severe motor-dominant neuropathy with IgM M-protein binding to the NeuAcalpha2-3Galbeta-moiety. J Neurol Sci 154:4- CrossRef
  22. Ortiz N, Rosa R, Gallardo E, Illa I, Tomas J, Aubry J, Sabater M, Santafé M (2001) IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J Neuroimmunol 119:114-23 CrossRef
  23. Lopate G, Choksi R, Pestronk A (2002) Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve 25:828-36 CrossRef
  24. Delval A, Stojkovic T, Vermersch P (2006) Relapsing sensorimotor neuropathy with ophthalmoplegia, antidisialosyl antibodies, and extramembranous glomerulonephritis. Muscle Nerve 33:274-77 CrossRef
  25. Iorio R, Capone F, Iannaccone E, Willison HJ, Modoni A, Tonali PA, Silvestri G (2009) SIADH in a patient with sensory ataxic neuropathy with anti-disialosyl antibodies (CANOMAD). J Neurol 256:1177-179 CrossRef
  26. Delmont E, Jeandel PY, Hubert AM, Marcq L, Boucraut J, Desnuelle C (2010) Successful treatment with rituximab of one patient with CANOMAD neuropathy. J Neurol 257:655-57 CrossRef
  27. Lehmann HC, Hoffmann FR, Meyer Zu, H?rste G, Hartung HP, Kieseier BC (2010) Central nervous system involvement in patients with monoclonal gammopathy and polyneuropathy. Eur J Neurol 17:1075-081 CrossRef
  28. Kam C, Balaratnam MS, Purves A, Mills KR, Riordan-Eva P, Pollock S, Bodi I, Munro NA, Bennett DL (2011) Canomad presenting without ophthalmoplegia and responding to intravenous immunoglobulin. Muscle Nerve 44:829-33 CrossRef
  29. Matà S, Borsini W, Ambrosini S, Toscani L, Barilaro A, Piacentini S, Sorbi S, Lolli F (2011) IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. Eur J Neurol 18:1067-073 CrossRef
  30. Sanvito L, Rajabally YA (2011) Optic neuropathy associated with CANOMAD: description of 2 cases. Muscle Nerve 44:451-55
  31. L?scher WN, Woertz A, Walln?fer M, Wanschitz JV, Luef G (2013) Successful treatment of CANOMAD with IVIg and rituximab. J Neurol 260:1168-170 CrossRef
  
• 作者单位：Abraham C. J. Stork (1)
  W-Ludo van der Pol (1)
  Hessel Franssen (1)
  Bart C. Jacobs (2)
  Nicolette C. Notermans (1)
  
  1. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500 3508 GA, 3584 CX, Utrecht, The Netherlands
  2. Departments of Neurology and Immunology, Erasmus Medical Center, ‘s Ggravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
  
• ISSN：1432-1459

文摘

The objective of this study was to investigate if the clinical and electrophysiological phenotype of patients with polyneuropathy associated with IgM monoclonal gammopathy (IgM-PNP) is related to the presence of antibodies against gangliosides or myelin-associated glycoprotein (MAG). We compared clinical and nerve conduction study (NCS) characteristics of 11 IgM-PNP patients with antibodies against asialo-GM1 or gangliosides (GM1, GD1a, GD1b, GM2 or GQ1b) to 11 consecutive IgM-PNP patients with anti-MAG neuropathy and to 9 IgM-PNP patients without antibodies against either MAG or gangliosides. Patients with anti-ganglioside antibodies could not be differentiated from those with anti-MAG antibodies based on clinical characteristics. However, within the group of anti-ganglioside antibody positive patients, antibodies against GD1b and GQ1b were associated with a purely sensory neuropathy (p?=?0.002), while asymmetric weakness with symmetric sensory loss was associated with anti-asialo-GM1 antibodies. In conclusion, polyneuropathy associated with IgM monoclonal gammopathy and anti-ganglioside antibodies clinically resembles anti-MAG neuropathy. Pure sensory neuropathy and marked asymmetry may suggest the presence of anti-ganglioside rather than anti-MAG antibodies.